ACROBiosystemsACROBiosystems

Brand Introduction

ACROBiosystems Group (Stock Code: 301080) is a multinational biotechnology company founded in 2010, with the vision of becoming an industry platform-based cornerstone enterprise providing key bioreagents, solutions, and innovative business models for the global biopharmaceutical and health industries. The company was listed on the ChiNext Board in 2021. ACROBiosystems Group operates globally across Asia, North America, and Europe, with offices, R&D centers, and manufacturing facilities in 16 cities across China, the United States, Switzerland, and other countries. To date, the company has served over 13,000 customers cumulatively and has established long-term, stable partnerships with renowned global pharmaceutical companies. The Group owns brands including ACROBiosystems, bioSeedin, Condense Capital, and ACRODiagnostics.

ACROBiosystems upholds the core brand values of "Quality, Innovation, and Service," and is committed to providing innovative products and solutions to overcome challenges across the entire biopharmaceutical R&D, manufacturing, and clinical workflow. Its main products and services include proteins, antibodies, kits, and analytical testing services, which are applied in drug screening and optimization, preclinical studies and clinical trials, drug manufacturing processes and process control (CMC), and diagnostic reagent development and optimization for diseases including oncology, autoimmune diseases, cardiovascular diseases, infectious diseases, and neurological disorders. ACROBiosystems sub-brands include Resilient Supply, Membrane Masterpiece, Star Staining, Aneuro, CytoPak, SAFENSURE, ComboX, ActiveMax, and GENPower.

ACROBiosystems Group's mission is to accelerate the R&D and market launch of biopharmaceuticals and to serve better clinical applications. Through its efforts—starting from delivering value to customers and extending to creating value for the entire global industry—the Group actively empowers its partners to accelerate the R&D, market launch, and better clinical application of various biopharmaceuticals, including targeted therapeutics and immunotherapeutic drugs, ultimately contributing to the cause of human health.